Rong Yang

发表

Case Report: Successful treatment of severe pneumocystis carinii pneumonia in a case series of primary nephrotic syndrome after receiving anti-CD20 monoclonal antibody therapy

G. Zhu, Ying Wu, Ping Wang, 2023, Frontiers in Pediatrics.

Changes in body composition with ritonavir-boosted and unboosted atazanavir treatment in combination with Lamivudine and Stavudine: a 96-week randomized, controlled study.

G. McComsey, Marina Mathew, D. McGrath, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence

E. Schiff, R. Fontana, F. Poordad, 2016, Hepatology.

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

J. Molina, G. Moyle, M. Mancini, 2008, The Lancet.

Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study

M. Johnson, K. Squires, J. Absalon, 2010, The Journal of antimicrobial chemotherapy.

Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1–Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE Study

J. Absalon, J. Molina, G. Moyle, 2010, Journal of acquired immune deficiency syndromes.

PRINCE-1: safety and efficacy of atazanavir powder and ritonavir liquid in HIV-1-infected antiretroviral-naïve and -experienced infants and children aged ≥3 months to <6 years

R. Strehlau, H. Hardy, T. Correll, 2015, Journal of the International AIDS Society.

A Nucleoside- and Ritonavir-Sparing Regimen Containing Atazanavir Plus Raltegravir in Antiretroviral Treatment-Naïve HIV-Infected Patients: SPARTAN Study Results

M. Kozal, R. Leavitt, F. Raffi, 2012, HIV clinical trials.

Virologic Failures on Initial Boosted-PI Regimen Infrequently Possess Low-Level Variants with Major PI Resistance Mutations by Ultra-Deep Sequencing

M. Kozal, B. Simen, Elizabeth P. St. John, 2012, PloS one.

Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine

Rong Yang, J. Uy, D. McGrath, 2011, AIDS care.

Prevalence and Clinical Significance of HIV Drug Resistance Mutations by Ultra-Deep Sequencing in Antiretroviral-Naïve Subjects in the CASTLE Study

Marco Mancini, M. Egholm, M. Kozal, 2010, PloS one.

Gastrointestinal tolerability and quality of life in antiretroviral-naïve HIV-1-infected patients: data from the CASTLE study

J. Absalon, M. Mancini, Jun Su, 2010, AIDS care.

96-Week Efficacy and Safety of Atazanavir, With and Without Ritonavir, in a HAART Regimen in Treatment-Naive Patients

U. Iloeje, Marina Mathew, D. McGrath, 2010, Journal of the International Association of Physicians in AIDS Care.

Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis.

G. Dore, G. Everson, P. Kwo, 2015, JAMA.